Literature DB >> 19027781

Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.

Mark J Perrin1, Rajesh N Subbiah, Jamie I Vandenberg, Adam P Hill.   

Abstract

The human Ether-a-go-go Related Gene (hERG) potassium channel plays a central role in regulating cardiac excitability and maintenance of normal cardiac rhythm. Mutations in hERG cause a third of all cases of congenital long QT syndrome, a disorder of cardiac repolarisation characterised by prolongation of the QT interval on the surface electrocardiogram, abnormal T waves, and a risk of sudden cardiac death due to ventricular arrhythmias. Additionally, the hERG channel protein is the molecular target for almost all drugs that cause the acquired form of long QT syndrome. Advances in understanding the structural basis of hERG gating, its traffic to the cell surface, and the molecular architecture involved in drug-block of hERG, are providing the foundation for rational treatment and prevention of hERG associated long QT syndrome. This review summarises the current knowledge of hERG function and dysfunction, and the areas of ongoing research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027781     DOI: 10.1016/j.pbiomolbio.2008.10.006

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  43 in total

Review 1.  HERG1 channelopathies.

Authors:  Michael C Sanguinetti
Journal:  Pflugers Arch       Date:  2009-11-22       Impact factor: 3.657

2.  Intracellular regions of the Eag potassium channel play a critical role in generation of voltage-dependent currents.

Authors:  Yong Li; Xinqiu Liu; Yuying Wu; Zhe Xu; Hongqin Li; Leslie C Griffith; Yi Zhou
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

3.  Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.

Authors:  Yamini Krishnan; Renjian Zheng; Christine Walsh; Yingying Tang; Thomas V McDonald
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-25       Impact factor: 1.976

4.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

5.  The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of Poisoning.

Authors:  Müjgan Büyükdeligöz; Nil Hocaoğlu; Kubilay Oransay; Yeşim Tunçok; Şule Kalkan
Journal:  Balkan Med J       Date:  2015-07-01       Impact factor: 2.021

6.  Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers.

Authors:  Katherine Campbell; Conrado J Calvo; Sergey Mironov; Todd Herron; Omer Berenfeld; José Jalife
Journal:  J Physiol       Date:  2012-10-22       Impact factor: 5.182

7.  Structure of the C-terminal region of an ERG channel and functional implications.

Authors:  Tinatin I Brelidze; Elena C Gianulis; Frank DiMaio; Matthew C Trudeau; William N Zagotta
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

8.  Predicting critical drug concentrations and torsadogenic risk using a multiscale exposure-response simulator.

Authors:  Francisco Sahli Costabal; Jiang Yao; Anna Sher; Ellen Kuhl
Journal:  Prog Biophys Mol Biol       Date:  2018-10-26       Impact factor: 3.667

9.  Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.

Authors:  Fatmahan Atalar; Tufan Tevfik Acuner; Naci Cine; Fatih Oncu; Dogan Yesilbursa; Ugur Ozbek; Solmaz Turkcan
Journal:  Behav Brain Funct       Date:  2010-05-28       Impact factor: 3.759

10.  The N-terminal tail of hERG contains an amphipathic α-helix that regulates channel deactivation.

Authors:  Chai Ann Ng; Mark J Hunter; Matthew D Perry; Mehdi Mobli; Ying Ke; Philip W Kuchel; Glenn F King; Daniela Stock; Jamie I Vandenberg
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.